• Mabwell on Oct. 18, 2026, announced plans to present Phase II results for 9MW2821 at the 2026 ESMO Congress.
• The Nectin-4-targeting antibody-drug conjugate was studied in advanced triple-negative breast cancer previously treated with ADCs carrying topoisomerase I inhibitor payloads.
• Results through April 10, 2026, showed tumor responses and disease control among 60 evaluable patients, supporting potential use following prior ADC treatment.
• The treatment showed a manageable safety profile, with no new safety signals observed during follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610182200PR_NEWS_USPR_____CN74849) on October 19, 2026, and is solely responsible for the information contained therein.